Skip to main content

Research Repository

Advanced Search

Oral ketamine vs placebo in patients with cancer-related neuropathic pain

Fallon, Marie T.; Wilcock, Andrew; Kelly, Caroline A.; Paul, James; Lewsley, Liz-Anne; Norrie, John; Laird, Barry J. A.

Authors

Marie T. Fallon

Andrew Wilcock

Caroline A. Kelly

James Paul

Liz-Anne Lewsley

John Norrie

Barry J. A. Laird



Abstract

Ketamine hydrochloride is used as an adjuvant treatment for cancer-related neuropathic pain, but evidence of its effectiveness is limited.1 Findings of a large trial investigating the use of ketamine for general cancer pain were negative, but the population studied did not specifically have neuropathic pain. A randomized trial of oral ketamine for cancer-related neuropathic pain has been called for, and the present trial addresses that need.

Citation

Fallon, M. T., Wilcock, A., Kelly, C. A., Paul, J., Lewsley, L., Norrie, J., & Laird, B. J. A. (2018). Oral ketamine vs placebo in patients with cancer-related neuropathic pain. JAMA Oncology, 4(6), 870-872. https://doi.org/10.1001/jamaoncol.2018.0131

Journal Article Type Article
Acceptance Date Jan 11, 2018
Online Publication Date Apr 5, 2018
Publication Date 2018-06
Deposit Date Apr 16, 2018
Publicly Available Date Apr 16, 2018
Journal JAMA Oncology
Print ISSN 2374-2437
Electronic ISSN 2374-2437
Publisher American Medical Association
Peer Reviewed Peer Reviewed
Volume 4
Issue 6
Pages 870-872
DOI https://doi.org/10.1001/jamaoncol.2018.0131
Public URL http://eprints.nottingham.ac.uk/id/eprint/51161
Publisher URL https://doi.org/10.1001/jamaoncol.2018.0131
Copyright Statement Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0

Files






You might also like



Downloadable Citations